VALUATION

How home care agencies are valued

A home care agency is normally valued as a multiple of adjusted EBITDA. Adjusted EBITDA is your profit after replacing your compensation with a market rate salary and removing one time or personal costs. The multiple depends on size, payer mix, referral concentration, caregiver retention, and how little the business depends on you.

Akim Guennani

By Akim Guennani, Founder · Updated September 2026

110

Home health and hospice deals announced in 2025

37%

2025 home health and hospice deals involving PE

4.7x

Median EBITDA multiple, home-based care deals under $10M EV

Step one: get to adjusted EBITDA

Tax returns rarely show what a buyer will pay for. The adjustment process, which a buyer later re tests in a quality of earnings review, typically includes these items.

Owner compensation
Replace your pay with what it would cost to hire someone in your role.
Personal expenses
Vehicles, travel, phones, and family payroll that a buyer will not inherit.
One time items
Legal settlements, startup costs of a new location, and pandemic era relief funds.
Run rate changes
Rate increases, new contracts, or closed lines that make trailing twelve months misleading.

Step two: the multiple

Multiples scale with size and with risk. Smaller agencies, heavy owner involvement, and concentrated referral sources pull the multiple down. Scale, clinical infrastructure, diversified payers, and a management team that runs the business pull it up. Certified Medicare home health generally prices above non medical personal care at the same EBITDA, because episodic revenue and the certification carry more strategic value.

As a reference point, Scope Research's 2025 review puts small, single-market personal care agencies at about 3x to 5x EBITDA and small Medicare-certified home health agencies at about 3x to 6x, rising to 5x to 9x for regional operators and higher for multi-state platforms. Its median for home-based care deals under $10 million of enterprise value is 4.7x.

Treat any published range as a starting point rather than a quote. The only number that matters is what specific buyers say about your specific agency, which is why we show owners several buyer views instead of one appraisal.

Step three: what you actually receive

Headline price and proceeds are different things. Cash at close, an earnout tied to future performance, rollover equity, a working capital settlement, and any escrow all change your outcome. A slightly lower price with more cash at close and no earnout is frequently the better deal.

EBITDA multiple ranges by segment and size

These are published ranges of adjusted EBITDA multiples for home care agencies. Personal care and home health come from Scope Research's 2025 review of home-based care deals, which sizes agencies by revenue: small means under about $5 million of revenue, regional about $5 million to $25 million, and large a multi-state platform. Hospice ranges come from 2026 industry benchmarks that size agencies by EBITDA: small under $500,000, mid-size $500,000 to $2 million, and large above $2 million.

For the smallest deals, Scope's database puts the median at 4.7x EBITDA (0.6x revenue) for home-based care transactions under $10 million of enterprise value, with the middle half between 4.1x and 6.5x. Most independent agencies sell inside the small-agency column. Treat every range as a starting point: the multiple a specific agency earns depends on payer mix, referral concentration, caregiver retention, and owner dependence.

SegmentSmall, single marketRegional / mid-sizeLarge platform
Personal care (non-medical)3x to 5x5x to 8x7x to 10x
Home health (Medicare-certified)3x to 6x6x to 9x9x to 12x+
Hospice4.5x to 6x5.5x to 7.5x7x to 9x

Understanding revenue vs. EBITDA multiples

In the home care industry, larger transactions are sometimes described in terms of revenue multiples, though EBITDA remains the primary driver for most private deals. For example, Addus HomeCare's $350 million acquisition of Gentiva's personal care assets was roughly 1.25x their $280 million annualized revenue. Similarly, Pennant's $80 million acquisition of Signature Healthcare at Home assets was about 1.07x its roughly $75 million of annual revenue. These are benchmarks, not rules.

While revenue multiples are easy to calculate, they don't account for profitability. A high-revenue agency with 2% margins is worth far less than a smaller agency with 15% margins. Buyers use EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) to compare the core operational profitability of different agencies. A 'normalized' EBITDA reflects what the business would earn under new management, removing your personal perks and one-time costs.

MetricHome Care (Personal)Home Health (Skilled)
Primary PayerMedicaid / Private PayMedicare / MA
Valuation FocusCaregiver Hours & RetentionClinical Outcomes & PDGM
Regulatory RiskState Licensing / Wage & HourFederal Audits / 36-Month Rule
Typical small-agency multiple3x to 5x EBITDA3x to 6x EBITDA

Factors that influence your multiple

Several qualitative factors can cause your valuation to deviate from the average. Size is a major factor; larger agencies often command higher multiples because they are perceived as more stable. Geographic density also matters; having 500 patients in one city is more efficient and valuable than 500 patients spread across an entire state. Payer concentration is another risk; if 90% of your revenue comes from one Medicaid waiver, a change in state policy could be devastating.

Management depth is equally important. If the agency cannot run for a week without you, a buyer will see it as a high-risk investment. A strong clinical director and a dedicated HR manager can reduce perceived owner-dependence. Finally, compliance is non-negotiable. Known or potential wage and hour liabilities may affect price, escrow, indemnity, or whether a buyer proceeds. Remember, this information is for educational purposes and is not financial advice.

Illustrative example: Enterprise Value Calculation

An agency has $1,000,000 in Adjusted EBITDA. A buyer offers a 6.0x multiple, resulting in an Enterprise Value of $6,000,000. However, the buyer identifies $200,000 in aged payroll tax liabilities and a $100,000 shortfall in the required working capital 'peg.' The final adjusted purchase price at the closing table would be $5,700,000 before other transaction costs.

The enterprise-to-equity bridge

It is vital to distinguish between the 'sticker price' and the cash you actually take home. The bridge from enterprise value to equity proceeds involves several steps. You start with the enterprise value, add any cash remaining in the business, and subtract all debt. You also adjust for working capital, which is the difference between current assets and current liabilities. If your working capital is below the agreed-upon target, the price is adjusted downward.

Other adjustments can include escrowed funds held by a third party to cover certain claims under the purchase agreement. You must also account for transaction expenses, such as fees for your accountant, M&A advisor, and attorney. By the time these adjustments are made, the cash at closing may be significantly different from the initial headline number. Consult with a qualified professional to map out your specific bridge.

Sources and methodology

Public transactions provide market context, not a valuation quote for a private practice. Illustrative examples use hypothetical assumptions and are not predictions. This guide is educational and is not legal, tax, accounting, or investment advice.

  1. 1. Addus Gentiva Closing Press Release (SEC Edgar). Confirms the $350M price and 16,000 daily patients for Addus/Gentiva.
  2. 2. Pennant Signature Asset Purchase (SEC EDGAR). Provides the $80M price and approximately $75M annual revenue for the Signature Healthcare acquisition.
  3. 3. Net Working Capital in M&A (BDO). Explains the importance of working capital adjustments in determining final equity proceeds.
  4. 4. Home Health Valuation Multiples and M&A Trends 2025 (Scope Research). EBITDA multiple ranges by segment and size for personal care and home health.
  5. 5. Valuation Multiples from Small Home Health and Hospice M&A Transactions (Scope Research). 4.7x median EBITDA multiple (4.1x to 6.5x interquartile) for home-based deals under $10M EV.

Reviewed September 2026

Questions owners ask

Straight answers, before you commit to anything.

What EBITDA multiple do home care agencies sell for?+

Published ranges for small agencies (under about $5 million of revenue) are roughly 3x to 5x adjusted EBITDA for non-medical personal care and 3x to 6x for Medicare-certified home health, per Scope Research's 2025 review. Regional operators reach about 5x to 9x and scaled platforms more. The median for home-based care deals under $10 million of enterprise value is 4.7x.

Is home care valued on revenue or EBITDA?+

EBITDA in nearly all cases. Revenue multiples appear only for very small agencies or license driven purchases where profitability is not meaningful yet.

Does a single large referral source hurt my value?+

Yes, when it is a large share of volume. Buyers either discount the price or shift the risk into an earnout. Diversifying before a sale is one of the highest return things an owner can do.

Can I find out what my agency is worth without committing to sell?+

Yes. Owners regularly send their details, see which buyers are interested and at what level, and decide to do nothing. There is no fee and no exclusivity.

Confidential inquiry

Tell us about your agency.

Everything you send stays between us. We never list or shop an agency, and nothing goes to a buyer without your explicit approval. There is no cost to you at any stage.